CAR-T
Most Read
STAT Plus: New data on CRISPR Therapeutics’ off-the-shelf CAR-T cancer therapy shows more remissions, no major safety issues
STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
STAT Plus: New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind
STAT Plus: Cellectis off-the-shelf CAR-T therapy grounded following patient’s toxic death
Insight into exhausted immune cells could open new doors for cancer therapy
